Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALE long-term pegcetacoplan extension study in C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis
NL-OMON58739Phase 3Active, not recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2023
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Apellis Pharmaceuticals. Primary endpoint: Log-transformed ratio of urine protein-to-creatinine ratio over time compared with pretreatment baseline. Started Dec 2023; status: active, not recruiting.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NL-OMON58739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58739.